Natera (NTRA) Earnings Date & Reports

Key Takeaways

• Natera, Inc. is scheduled to report its third-quarter 2026 results on November 5, 2026, after the market close.
• Wall Street consensus points to revenue near $707 million and a loss of roughly $0.26 per share for the quarter.
• Investors will be watching Signatera volume, the company's molecular residual disease (MRD) oncology test, as a core growth driver.
• Natera has beaten consensus earnings-per-share (EPS) estimates in six of its last eight quarters, setting a high bar for this report.
• Management raised its full-year 2026 revenue guidance in August, signaling confidence in sustained demand across its testing portfolio.
• For more context on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• You can also explore Trending AI Robots to see how automated strategies are approaching stocks like Natera.

Earnings Context and Why It Matters

Natera's third-quarter report is a key checkpoint for one of the fastest-growing names in precision diagnostics. The company has built its reputation on cell-free DNA (cfDNA) testing, spanning non-invasive prenatal screening, organ transplant monitoring, and—most importantly—its Signatera MRD test for cancer recurrence monitoring. Recent quarters have shown powerful momentum: second-quarter 2026 revenue rose to about $753 million, well ahead of estimates, and management lifted its full-year outlook. Because the stock has already climbed sharply on that strength, this report tests whether the company can keep growing rapidly enough to justify investor enthusiasm, making the update significant for both the business and the broader healthcare-diagnostics sector.

Earnings Expectations

For the third quarter of 2026, the analyst consensus calls for revenue of approximately $707 million and a net loss of roughly $0.26 per share, according to aggregated estimates. That compares with revenue of about $592 million and a loss of $0.64 per share in the same period a year earlier, implying expected year-over-year revenue growth of roughly 19%. Key metrics to watch include total test volumes, the sequential growth in Signatera clinical MRD units, gross margin, and any update to the company's full-year 2026 revenue guidance range of $2.85 billion to $2.91 billion. Natera has beaten consensus EPS expectations in six of the last eight quarters, and its prior report topped revenue forecasts by a double-digit percentage, so investors will be closely tracking whether that trend continues.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Natera, it offers a structured way to surface comparable opportunities across the diagnostics and healthcare sectors.

Market Reaction and Investor Sentiment

Sentiment heading into the report is broadly optimistic but priced for execution. Natera's shares have advanced strongly over the past year and were trading near the upper end of their 52-week range as the quarter approached, reflecting enthusiasm for the company's oncology franchise and its improving cash-flow trajectory. That backdrop raises the stakes: a strong print may need to be accompanied by guidance reaffirmation or upside to sustain momentum, while any sign of slowing Signatera volume growth or margin pressure could trigger outsized volatility. Investors will also be listening for commentary on reimbursement and pricing, which have historically been important swing factors for the stock around earnings.

Forward Outlook and Key Factors to Monitor

Looking beyond the print, the central question is whether Signatera can keep scaling. Clinical MRD volume rose 56% year over year in the second quarter, and investors will want evidence that this trajectory is intact. Growth in this segment is the main engine behind Natera's valuation, so quarterly test counts and average selling prices (ASPs) will be scrutinized closely.

Cost discipline and margins also matter. The company improved gross margin to 65% last quarter and reduced days sales outstanding, signaling better cash collection. Maintaining that efficiency while reinvesting in commercialization and new indications will be important as the business scales toward positive full-year cash flow.

Finally, watch for updates on reimbursement decisions and coverage milestones, which management has flagged as meaningful long-term catalysts for pricing. Broader industry dynamics—including competition in the liquid-biopsy space and healthcare spending conditions—will continue to shape how investors interpret the company's growth story in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations